MCID: ALC007
MIFTS: 70

Alcohol Dependence

Categories: Cancer diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Alcohol Dependence

MalaCards integrated aliases for Alcohol Dependence:

Name: Alcohol Dependence 58 12 77 38 30 6 15 41 17
Alcoholism 58 12 56 15
Aerodigestive Tract Cancer, Squamous Cell, Alcohol-Related, Protection Against 58 13 6
Alcohol Dependence, Protection Against 58 13
Alcohol Dependence, Susceptibility to 58 6
Alcoholic Intoxication, Chronic 74
Alcoholism, Susceptibility to 6
Pharyngeal Neoplasms 74

Characteristics:

OMIM:

58
Inheritance:
probably multifactorial, genetically influenced


Classifications:



External Ids:

Disease Ontology 12 DOID:0050741
OMIM 58 103780
KEGG 38 H01611
SNOMED-CT 69 66590003
MedGen 43 C0001973
SNOMED-CT via HPO 70 88425004

Summaries for Alcohol Dependence

Disease Ontology : 12 A substance dependence that is characterized by tolerance, withdrawal symptoms, increasing use, persistent desire to decrease consumption, time spent obtaining or recovering from alcohol caused by a physical and psychological dependence on alcohol.

MalaCards based summary : Alcohol Dependence, also known as alcoholism, is related to fetal alcohol syndrome and alcoholic neuropathy. An important gene associated with Alcohol Dependence is ADH1B (Alcohol Dehydrogenase 1B (Class I), Beta Polypeptide), and among its related pathways/superpathways are Alcoholism and Peptide ligand-binding receptors. The drugs Ethanol and Gabapentin have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and liver, and related phenotypes are abnormality of the nervous system and alcoholism

Wikipedia : 77 Alcohol dependence is a previous (DSM-IV and ICD-10) psychiatric diagnosis in which an individual is... more...

Description from OMIM: 103780

Related Diseases for Alcohol Dependence

Diseases related to Alcohol Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1312)
# Related Disease Score Top Affiliating Genes
1 fetal alcohol syndrome 34.9 ALDH2 ADH7 ADH1B
2 alcoholic neuropathy 34.6 ALDH2 ADH4
3 alcoholic psychosis 34.5 SLC6A4 SLC6A3 HTR2A DRD2
4 alcohol-induced mental disorder 34.1 SLC6A4 SLC6A3 DRD2
5 alcohol abuse 33.3 SLC6A4 HTR2A GABRA2 DRD4 DRD2 CYP2E1
6 migraine with or without aura 1 32.3 SLC6A4 MAOA HTR2A HTR1B DRD2
7 psychotic disorder 31.8 SLC6A4 SLC6A3 HTR2A DRD4 DRD2
8 depression 31.7 SLC6A4 MAOA HTR2A
9 methanol poisoning 31.6 CYP2E1 ADH1C ADH1B
10 anxiety 31.5 SLC6A4 MAOA HTR2A
11 bipolar disorder 31.1 SLC6A4 SLC6A3 HTR2A DRD2
12 schizophrenia 31.0 SLC6A4 SLC6A3 MAOA HTR2A HTR1B DRD4
13 personality disorder 30.9 SLC6A4 SLC6A3 MAOA HTR2A HTR1B DRD4
14 liver cirrhosis 30.9 CYP2E1 ALDH2 ADH1C ADH1B
15 post-traumatic stress disorder 30.9 SLC6A4 MAOA HTR2A DRD2
16 drug dependence 30.9 SLC6A4 OPRM1 OPRK1 DRD2 CHRNA6
17 opiate dependence 30.8 SLC6A4 OPRM1 OPRK1 DRD2
18 conduct disorder 30.8 ALDH2 DRD2 DRD4 MAOA SLC6A3 SLC6A4
19 pathological gambling 30.8 SLC6A4 SLC6A3 MAOA HTR2A DRD4 DRD2
20 major depressive disorder 30.8 SLC6A4 SLC6A3 MAOA HTR2A HTR1B DRD4
21 antisocial personality disorder 30.7 SLC6A4 SLC6A3 MAOA HTR1B DRD2 ALDH2
22 attention deficit-hyperactivity disorder 30.7 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A HTR1B
23 substance abuse 30.6 SLC6A4 SLC6A3 MAOA HTR1B GABRA2 DRD4
24 cocaine dependence 30.6 SLC6A4 SLC6A3 OPRM1 OPRK1 DRD2
25 tobacco addiction 30.6 TAS2R16 SLC6A4 SLC6A3 OPRM1 MAOA HTR2A
26 panic disorder 30.6 SLC6A4 MAOA HTR2A
27 bulimia nervosa 30.6 SLC6A4 HTR2A HTR1B
28 disease of mental health 30.6 DRD2 DRD4 HTR2A MAOA OPRM1 SLC6A3
29 mood disorder 30.5 SLC6A4 MAOA HTR2A HTR1B DRD4 DRD2
30 cocaine abuse 30.5 SLC6A4 SLC6A3 DRD2
31 heroin dependence 30.4 OPRM1 DRD4 DRD2
32 alcoholic liver cirrhosis 30.4 CYP2E1 ALDH2 ADH4 ADH1C ADH1B
33 eating disorder 30.4 SLC6A4 SLC6A3 DRD2
34 alcoholic pancreatitis 30.4 CYP2E1 ALDH2 ADH1B
35 mental depression 30.4 SLC6A4 MAOA HTR2A
36 borderline personality disorder 30.4 SLC6A4 MAOA HTR2A HTR1B
37 substance dependence 30.4 SLC6A4 SLC6A3 OPRM1 OPRK1 MAOA HTR1B
38 endogenous depression 30.3 SLC6A4 MAOA HTR2A
39 gilles de la tourette syndrome 30.3 SLC6A3 DRD4 DRD2
40 opioid addiction 30.3 OPRM1 OPRK1 DRD2
41 social phobia 30.2 SLC6A4 MAOA DRD2
42 phobic disorder 30.2 SLC6A4 OPRK1 MAOA
43 dysthymic disorder 30.2 SLC6A4 MAOA HTR2A
44 agoraphobia 30.2 SLC6A4 OPRK1 MAOA
45 generalized anxiety disorder 30.2 SLC6A4 MAOA HTR2A DRD2
46 paranoid schizophrenia 30.2 SLC6A4 MAOA HTR2A
47 schizoaffective disorder 30.2 SLC6A4 HTR2A DRD2
48 obsessive-compulsive disorder 30.1 DRD2 DRD4 HTR1B SLC6A4 SLC6A3 MAOA
49 oppositional defiant disorder 30.1 SLC6A4 SLC6A3 MAOA DRD4 DRD2
50 premature ejaculation 30.1 SLC6A4 SLC6A3 HTR1B

Graphical network of the top 20 diseases related to Alcohol Dependence:



Diseases related to Alcohol Dependence

Symptoms & Phenotypes for Alcohol Dependence

Human phenotypes related to Alcohol Dependence:

33
# Description HPO Frequency HPO Source Accession
1 abnormality of the nervous system 33 HP:0000707
2 alcoholism 33 HP:0030955

Symptoms via clinical synopsis from OMIM:

58
Neuro:
alcoholism

Misc:
25 to 50% lifetime risk for sons and brothers of severely alcoholic men

Clinical features from OMIM:

103780

GenomeRNAi Phenotypes related to Alcohol Dependence according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ADH1B ADH1C ADH4 ADH7 ALDH2 ALDH9A1

MGI Mouse Phenotypes related to Alcohol Dependence:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.18 ADH7 ALDH2 CYP2E1 DRD2 DRD4 GABRA2
2 homeostasis/metabolism MP:0005376 10.07 ADH1C ADH7 ALDH2 CYP2E1 DRD2 DRD4
3 endocrine/exocrine gland MP:0005379 9.97 ALDH2 DRD2 GATA4 HTR1B HTR2A OPRK1
4 integument MP:0010771 9.81 ALDH2 ALDH9A1 DRD2 GABRA2 GATA4 OPRK1
5 muscle MP:0005369 9.5 ALDH2 DRD2 GATA4 HTR1B HTR2A SLC6A3
6 nervous system MP:0003631 9.4 ADH7 ALDH2 CHRNA6 DRD2 DRD4 GABRA2

Drugs & Therapeutics for Alcohol Dependence

Drugs for Alcohol Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 513)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 64-17-5 702
2
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 60142-96-3 3446
3
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 77337-76-9 71158
4
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 97240-79-4 5284627
5
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 16590-41-3 5360515
6
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2 148553-50-8 5486971
7
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
8
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 62-31-7, 51-61-6 681
9
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 34841-39-9, 34911-55-2 444
10
Disulfiram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 97-77-8 3117
11
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-36-2 446220 5760
12
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 616-91-1 12035
13
Prazosin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19216-56-9 4893
14
Nicotine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 54-11-5 942 89594
15
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 249296-44-4 5310966
16
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
17
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 99614-02-5 4595
18
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 1 465-65-6 5284596
19
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 68291-97-4 5734
20
Lorazepam Approved Phase 4,Phase 2,Phase 1 846-49-1 3958
21
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
22
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-09-7, 1994-09-7 2337
23
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1401-55-4
24
Lamotrigine Approved, Investigational Phase 4,Phase 3 84057-84-1 3878
25
Methylphenidate Approved, Investigational Phase 4,Phase 1,Early Phase 1 113-45-1 4158
26
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3 129722-12-9 60795
27
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2 19982-08-2 4054
28
Citalopram Approved Phase 4,Phase 2,Phase 1,Not Applicable 59729-33-8 2771
29
Sodium oxybate Approved Phase 4 502-85-2 5360545
30
Oxazepam Approved Phase 4 604-75-1 4616
31
Levetiracetam Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 102767-28-2 441341
32
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
33
Clozapine Approved Phase 4 5786-21-0 2818
34
Baclofen Approved Phase 4,Phase 2,Phase 3,Phase 1 1134-47-0 2284
35
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
36
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
37
Midazolam Approved, Illicit Phase 4,Phase 1,Phase 2,Not Applicable 59467-70-8 4192
38
Dutasteride Approved, Investigational Phase 4,Not Applicable 164656-23-9 152945 6918296
39
Icodextrin Approved, Investigational Phase 4 337376-15-5
40
Spironolactone Approved Phase 4 52-01-7, 1952-01-7 5833
41
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 439-14-5 3016
42
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
43
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2 132539-06-1 4585
44
Acetylcholine Approved, Investigational Phase 4,Phase 2 51-84-3 187
45
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
46
Methadone Approved Phase 4,Phase 2 76-99-3 4095
47
Simvastatin Approved Phase 4 79902-63-9 54454
48
Sargramostim Approved, Investigational Phase 4 123774-72-1, 83869-56-1
49
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3 6493-05-6 4740
50
Lenograstim Approved, Investigational Phase 4 135968-09-1

Interventional clinical trials:

(show top 50) (show all 1317)
# Name Status NCT ID Phase Drugs
1 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
2 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
3 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4 Topiramate
4 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4 Naltrexone;Acamprosate
5 Pregabalin for Alcohol Dependence Unknown status NCT02205879 Phase 4 Pregabalin;Placebo
6 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
7 Antabuse in Severe Alcoholism: an Open Controlled Study Unknown status NCT00431262 Phase 4 antabuse (disulfiram)
8 Effect of N-acetylcysteine on Alcohol and Cocaine Use Disorders: A Double-Blind Randomized Controlled Trial. Unknown status NCT03018236 Phase 4 Alcohol N-acetylcysteine;Alcohol Placebo;Cocaine N-acetylcysteine;Cocaine Placebo
9 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
10 Extended-release Naltrexone for Alcohol Dependence in Primary Care Completed NCT00620750 Phase 4 Extended release injectable naltrexone (Vivitrol)
11 Study of Campral (Acamprosate) for Alcohol Dependence in a Family Medicine Clinic Completed NCT00381043 Phase 4 Acamprosate (Campral)
12 Pharmacotherapy for Alcohol Dependence in Convicted Drinking Drivers Terminated NCT01638377 Phase 4 Naltrexone;Control
13 A Controlled Trial of Topiramate Treatment for Alcohol Dependence in Veterans With PTSD Recruiting NCT01749215 Phase 4 Topiramate;placebo
14 Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care Terminated NCT02195817 Phase 4 Selincro® 18 mg with continuous psychosocial support: Cohort A
15 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
16 A Randomized Clinical Trial of Alcohol Care Management Completed NCT00419315 Phase 4
17 Trial of Seroquel SR for Alcohol Dependence and Comorbid Anxiety Completed NCT00352469 Phase 4 Seroquel XR
18 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
19 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
20 Identifying Multiple Mechanisms of Change in Alcoholism Treatment Completed NCT01168960 Phase 4
21 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
22 Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial Terminated NCT00461890 Phase 4 Injectable Naltrexone
23 Prazosin Alcohol Dependence IVR Study Completed NCT00167687 Phase 4 prazosin
24 Injectable Versus Oral Naltrexone Treatment of Alcohol Dependence In Serious Mental Illness (SMI) Completed NCT00453804 Phase 4 injectable naltrexone;oral naltrexone
25 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
26 Comparative Trial Of Disulfiram, Naltrexone And Acamprosate In The Treatment Of Alcohol Dependence Completed NCT00435435 Phase 4 Disulfiram;Acamprosate;Naltexone
27 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
28 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) Completed NCT00453609 Phase 4 long-lasting injectable naltrexone
29 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Completed NCT01015586 Phase 4 Lamotrigine;Placebo
30 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
31 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Naltrexone 50 Mg;Placebo
32 Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Completed NCT00000437 Phase 4 Naltrexone Tablet and Nicotine Patch;Naltrexone Tablet and Placebo Patch;Placebo Tablet and Nicotine Patch;Placebo Tablet and Placebo Patch
33 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
34 Managing Alcoholism in People Who Do Not Respond to Naltrexone Completed NCT00115037 Phase 4 Naltrexone;placebo
35 Behavioral Therapy Plus Naltrexone for Alcoholism Completed NCT00000456 Phase 4 naltrexone (Revia)
36 Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone) Completed NCT00006489 Phase 4 Naltrexone;Placebo
37 Naltrexone Treatment for Alcoholism Completed NCT00000438 Phase 4 naltrexone (Revia)
38 Individually Adapted Therapy of Alcoholism Completed NCT00317031 Phase 4 Acamprosate or Naltrexone
39 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
40 Sertraline for Alcohol Dependence and Depression Completed NCT00004554 Phase 4 naltrexone (Revia);sertraline (Zoloft);Placebo
41 Paliperidone Palmitate Efficacy and Safety in Bipolar Disorder Complicated by Alcoholism Withdrawn NCT01211704 Phase 4 Paliperidone Palmitate;Placebo
42 Naltrexone Maintenance Treatment of Alcoholism Completed NCT00000450 Phase 4 Naltrexone Tablet;Matched Placebo Tablet
43 Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care Active, not recruiting NCT01893827 Phase 4 XR-NTX (Extended-Release Naltrexone);Oral Naltrexone (O-NTX)
44 Treatment of Patients Suffering of Alcohol Dependence and Impaired Liver Function With Selincro® As-needed Use Completed NCT02197598 Phase 4 nalmefene
45 Study of Aripiprazole in Subjects With Alcoholism Completed NCT00082199 Phase 4 Aripiprazole;Placebo
46 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4 nicotine replacement patch
47 Pilot Study of Depot NTX in Homeless Veterans Terminated NCT01155869 Phase 4 Depot naltrexone;Oral Naltrexone
48 Effectiveness of Naltrexone Versus Placebo to Reduce Craving for Alcohol With Evaluation of Genetic Variability. Completed NCT00366626 Phase 4 Naltrexone;Placebo
49 Efficacy Study of Memantine Hydrochloride and Escitalopram for the Treatment of Co-Morbid Depression and Alcoholism. Completed NCT00368862 Phase 4 Ebixa (memantine hydrochloride);Cipralex (escitalopram)
50 Acamprosate in Alcoholics With Comorbid Anxiety or Depression Completed NCT00330174 Phase 4 Acamprosate

Search NIH Clinical Center for Alcohol Dependence

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Alcohol Dependence

Genetic tests related to Alcohol Dependence:

# Genetic test Affiliating Genes
1 Alcohol Dependence 30 ADH1B ADH1C GABRA2 HTR2A

Anatomical Context for Alcohol Dependence

MalaCards organs/tissues related to Alcohol Dependence:

42
Brain, Testes, Liver, Cortex, Heart, Prefrontal Cortex, Eye

Publications for Alcohol Dependence

Articles related to Alcohol Dependence:

(show top 50) (show all 4833)
# Title Authors Year
1
Shared additive genetic variation for alcohol dependence among subjects of African and European ancestry. ( 29178570 )
2019
2
Association of serotonin and GABA pathway gene polymorphisms with alcohol dependence: A preliminary study. ( 29673739 )
2019
3
Mindfulness-based relapse prevention for alcohol dependence: Findings from a randomized controlled trial. ( 30898331 )
2019
4
Developmental Trajectories of Religious Service Attendance: Predictors of Nicotine Dependence and Alcohol Dependence/Abuse in Early Midlife. ( 30879207 )
2019
5
DRD2 methylation and regional grey matter volumes in young adult offspring from families at ultra-high risk for alcohol dependence. ( 30877890 )
2019
6
Correlations between sex-related hormones, alcohol dependence and alcohol craving. ( 30840924 )
2019
7
Ventral Visual Pathway-Cerebellar Circuit Deficits in Alcohol Dependence: Long- and Short-Range Functional Connectivity Density Study. ( 30809188 )
2019
8
Machine learning vs addiction therapists: A pilot study predicting alcohol dependence treatment outcome from patient data in behavior therapy with adjunctive medication. ( 30797388 )
2019
9
Stressful life events are associated with striatal dopamine receptor availability in alcohol dependence. ( 30747311 )
2019
10
Hazardous alcohol consumption and risk of alcohol dependence present different neurophysiological correlates. ( 30741400 )
2019
11
Alcohol dependence treating agent, acamprosate, prevents traumatic brain injury-induced neuron death through vesicular zinc depletion. ( 30731068 )
2019
12
Pellagra and Alcohol Dependence Syndrome: Findings From a Tertiary Care Addiction Treatment Centre in India. ( 30721993 )
2019
13
Serotonin transporter gene linked polymorphism (5-HTTLPR) determines progredience of alcohol dependence in Belarusian young males. ( 30708239 )
2019
14
Clinical implications of cognitive impairment and alcohol dependence. ( 30699230 )
2019
15
The impact of intimate partner violence, depressive symptoms, alcohol dependence, and perceived stress on 30-year cardiovascular disease risk among young adult women: A multiple mediation analysis. ( 30695719 )
2019
16
Modeling the Potential Impact of Changing Access Rates to Specialist Treatment for Alcohol Dependence for Local Authorities in England: The Specialist Treatment for Alcohol Model (STreAM). ( 30681953 )
2019
17
Estrogen receptor 1 gene variants and estradiol activities in alcohol dependence. ( 30677468 )
2019
18
Positive and negative reinforcement are differentially associated with alcohol consumption as a function of alcohol dependence. ( 30667237 )
2019
19
DNA Methylation of the Leptin Gene Promoter is Altered by Chronic Alcohol Exposure in an Animal Model for Alcohol Dependence. ( 30650427 )
2019
20
The role of matrix metalloproteinase-9 in negative reinforcement learning and plasticity in alcohol dependence. ( 30648329 )
2019
21
Associations of BRAP polymorphisms with the risk of alcohol dependence and scores on the Alcohol Use Disorders Identification Test. ( 30636874 )
2019
22
A Pilot Randomized, Placebo-Controlled Trial of Glycine for Treatment of Schizophrenia and Alcohol Dependence. ( 30633660 )
2019
23
Alcohol Dependence, Hypoglycemia, and Transient Movement Disorders. ( 30620452 )
2019
24
Pharmacotherapeutic options for co-morbid depression and alcohol dependence. ( 30602322 )
2019
25
A Middle-Aged Man With Alcoholism and a Nonhealing Corneal Ulcer. ( 30869770 )
2019
26
Soluble α-Klotho in Liver Cirrhosis and Alcoholism. ( 30860544 )
2019
27
Epidemiology of Alcohol Consumption and Societal Burden of Alcoholism and Alcoholic Liver Disease. ( 30454831 )
2019
28
Influence of experimental alcoholism on the repair process of bone defects filled with beta-tricalcium phosphate. ( 30875652 )
2019
29
Genetics of Alcoholism. ( 30852706 )
2019
30
Gene and cell therapy on the acquisition and relapse-like binge drinking in a model of alcoholism: translational options. ( 30820030 )
2019
31
Association Between Age and Familial Risk for Alcoholism on Functional Connectivity in Adolescence. ( 30768382 )
2019
32
Analysis of whole genome-transcriptomic organization in brain to identify genes associated with alcoholism. ( 30765688 )
2019
33
Never Mind Its Past Cocaine and Celery: Celerina's Alcohol "Treated" Alcoholism. ( 30762633 )
2019
34
Widespread Cognitive Deficits in Alcoholism Persistent Following Prolonged Abstinence: An Updated Meta-analysis of Studies That Used Standardised Neuropsychological Assessment Tools. ( 30668621 )
2019
35
Murine Drinking Models in the Development of Pharmacotherapies for Alcoholism: Drinking in the Dark and Two-bottle Choice. ( 30663649 )
2019
36
Alcoholism as a predictor for pseudarthrosis in primary spine fusion: An analysis of risk factors and 30-day outcomes for 52,402 patients from 2005 to 2013. ( 30662235 )
2019
37
Altered frontostriatal white matter microstructure is associated with familial alcoholism and future binge-drinking in adolescence. ( 30636769 )
2019
38
Intranasal erythropoietin ameliorates neurological function impairments and neural pathology in mice with chronic alcoholism by regulating autophagy‑related Nrf2 degradation. ( 30535439 )
2019
39
Introduction: Alcohol and Alcoholism. ( 30454824 )
2019
40
Neurological, nutritional and alcohol consumption factors underlie cognitive and motor deficits in chronic alcoholism. ( 29243370 )
2019
41
Treatment of alcohol dependence. Alcohol and homelessness: social point of view. ( 29912211 )
2018
42
Prevalence Estimates of ADHD in a Sample of Inpatients With Alcohol Dependence. ( 29308693 )
2018
43
Short message service (SMS) reminders improve treatment attendance in alcohol dependence, but are less effective for patients high in impulsivity. ( 29975880 )
2018
44
Italian Guidelines for the treatment of alcohol dependence. ( 29912210 )
2018
45
Religiosity, Guilt, Altruism and Forgiveness in Alcohol Dependence: Results of a Cross-sectional and Prospective Cohort Study. ( 29912267 )
2018
46
Lack of association between MTHFR C677T Gene polymorphism with alcohol dependence: A meta-analysis of case-control studies. ( 29953924 )
2018
47
Self-defining memories related to alcohol dependence and their integration in the construction of the self in a sample of abstinent alcoholics. ( 29944064 )
2018
48
The need for precise answers for the goals of precision medicine in alcohol dependence to succeed. ( 29930386 )
2018
49
Mecamylamine treatment for alcohol dependence: a randomized controlled trial. ( 28710873 )
2018
50
Association of alcohol dehydrogenase 1C gene *1/*2 polymorphism with alcohol Dependence(AD) in Turkey: A meta-analysis. ( 29438797 )
2018